{"filings":[{"id":649796,"accession_number":"0001437749-26-018318","cik":1595248,"company_name":"Genprex, Inc.","ticker":"GNPX","form_type":"8-K","filed_at":"2026-05-26T12:03:22+00:00","items":["8.01","9.01"],"status":"ready","headline":"Genprex reports positive predictive biomarker data for Reqorsa in NSCLC at ASCO 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["In NSCLC patients, Trop-2 H-score >100 and PTEN H-score <100 correlated with prolonged PFS (p=0.05, p=0.03).","Data from 18 patients across Acclaim-1 (osimertinib), Acclaim-2 (pembrolizumab), and Acclaim-3 (atezolizumab) trials.","High (3+) Trop-2 expression showed near-significant correlation with PFS (p=0.053); will be further investigated as biomarker.","In SCLC patients, Trop-2 levels were universally low; no significant correlation with PFS observed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":8431010.683498647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":77966,"accession_number":"0001437749-26-016883","cik":1595248,"company_name":"Genprex, Inc.","ticker":"GNPX","form_type":"8-K","filed_at":"2026-05-14T12:05:14+00:00","items":["8.01","9.01"],"status":"ready","headline":"Genprex diabetes gene therapy GPX-002 reverses hyperglycemia in T2D mouse model","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preclinical data presented at ASGCT 2026 showed GPX-002 reversed hyperglycemia in Type 2 diabetic mice within 4 weeks.","Treatment improved β-cell function: increased insulin granules, improved glucose-stimulated insulin secretion vs controls.","β-cell-specific targeting (RIP-PM-GFP) also reversed hyperglycemia, indicating enhanced β-cell maturation.","Approach is translatable to humans via endoscopic retrograde cholangiopancreatography delivery to the pancreas."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8431010.683498647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93957,"accession_number":"0001437749-26-013989","cik":1595248,"company_name":"Genprex, Inc.","ticker":"GNPX","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Genprex granted Israel patent for Reqorsa gene therapy with PD-1 antibodies","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Israel Patent Office granted patent covering Reqorsa (quaratusugene ozeplasmid) in combination with PD-1 antibodies for cancer treatment.","Patent expands IP portfolio previously granted in U.S., Japan, Mexico, Russia, Australia, Chile, China, Singapore, and Europe.","Reqorsa is initially being developed for lung cancer; preclinical data shows complementarity with targeted drugs and immunotherapies.","Israel lung cancer cases rose 33% in a decade; 200 new cases/month; leading cancer death cause in 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":8431010.683498647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93956,"accession_number":"0001437749-26-013534","cik":1595248,"company_name":"Genprex, Inc.","ticker":"GNPX","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Genprex' GPX-002 reverses hyperglycemia in T2D mouse models; data at ASGCT 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["GPX-002 (Pdx1/MafA gene therapy) reversed hyperglycemia in HFD-induced T2D mouse models within 4 weeks post-treatment.","Islets from treated mice showed insulin secretion similar to normal-diet mice; improved beta-cell function and maturation.","Treatment increased mature insulin granules and decreased immature granules in beta cells.","Approach deemed potentially translatable to humans via endoscopic retrograde cholangiopancreatography (ERCP).","Data to be presented at ASGCT Annual Meeting, May 11-15, 2026 in Boston."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":8431010.683498647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93955,"accession_number":"0001437749-26-012879","cik":1595248,"company_name":"Genprex, Inc.","ticker":"GNPX","form_type":"8-K","filed_at":"2026-04-21T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Genprex inks new MD Anderson SRA for Reqorsa biomarkers; trial updates show partial responses","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New Sponsored Research Agreement with UT MD Anderson to study TROP2 and PTEN as biomarkers for Reqorsa in NSCLC and SCLC.","Acclaim-1 Phase 2a enrolling; Phase 1 showed no DLTs, one patient had partial remission for ~42 months (60 courses) on Reqorsa+Tagrisso.","Acclaim-3 Phase 2 enrolling; Phase 1 showed no DLTs, one patient had unconfirmed partial remission after 24 cycles (>18 months) on Reqorsa+Tecentriq.","Both trials combine Reqorsa (quaratusugene ozeplasmid) with approved targeted therapies; early signs of efficacy reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8431010.683498647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105985,"accession_number":"0001437749-26-008733","cik":1595248,"company_name":"Genprex, Inc.","ticker":"GNPX","form_type":"8-K","filed_at":"2026-03-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Genprex announces positive preclinical data for Reqorsa at AACR 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["TROP2 and PTEN identified as potential biomarkers of primary resistance to TUSC2 gene therapy; 50% of NSCLC cell lines resistant.","Reqorsa plus alectinib achieved 79% tumor shrinkage in ALK+ sensitive model, 23% improvement vs alectinib alone.","In alectinib-resistant model, Reqorsa + alectinib produced synergistic tumor reduction and improved overall survival (p=0.0001).","TUSC2 restoration enhanced NK cell cytotoxicity; 67% of Tusc2 KO mice and 33% of wild-type mice achieved complete tumor regression.","Findings support progression toward clinical trials for ALK+ NSCLC and biomarker-guided patient selection."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8431010.683498647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105984,"accession_number":"0001437749-26-004954","cik":1595248,"company_name":"Genprex, Inc.","ticker":"GNPX","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Genprex wins Japanese and European patent grants for REQORSA combos; Acclaim-3 update","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Japanese Patent Office issued favorable Appeal Decision to grant patent for REQORSA + PD-L1 antibodies.","European Patent Office granted patent for REQORSA + PD-1 antibodies to treat cancer.","Acclaim-3 Phase 2 expansion: enrollment of first 25 patients for interim analysis expected by H1 2026; interim analysis in H2 2026.","Phase 2 primary endpoint: 18-week progression-free survival rate; trial targets ~50 patients with ES-SCLC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":8431010.683498647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105983,"accession_number":"0001437749-26-003577","cik":1595248,"company_name":"Genprex, Inc.","ticker":"GNPX","form_type":"8-K","filed_at":"2026-02-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Genprex gets Australian patent acceptance for Reqorsa+PD-L1; adds trial site","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IP Australia issued Notice of Acceptance on Feb 5, 2026 for patent covering Reqorsa + PD-L1 antibodies in cancer.","Opened additional Acclaim-3 clinical trial site at University of Kentucky; plans more sites to expand enrollment.","Acclaim-3 Phase 2 expansion targets ~50 patients; interim analysis after 25th patient expected in H2 2026.","Patent already granted in US and Korea; pending in Europe, Canada, Brazil, China, and Israel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":8431010.683498647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105982,"accession_number":"0001437749-26-000995","cik":1595248,"company_name":"Genprex, Inc.","ticker":"GNPX","form_type":"8-K","filed_at":"2026-01-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Genprex regains Nasdaq minimum $2.5M equity compliance; one-year monitoring imposed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq Compliance Notice on Jan 7, 2026, reaffirming compliance with Listing Rule 5550(b)(1).","Mandatory Panel Monitor runs through Jan 7, 2027; any deficiency within that period triggers delisting without cure.","If staff finds non-compliance during monitoring, delist determination letter issued; company may request new hearing.","Previously disclosed non-compliance letter from Nasdaq on Aug 19, 2025 has been resolved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":8431010.683498647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105981,"accession_number":"0001437749-26-000694","cik":1595248,"company_name":"Genprex, Inc.","ticker":"GNPX","form_type":"8-K","filed_at":"2026-01-07T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Genprex advances diabetes gene therapy GPX-002 into T2D preclinical studies, plans FDA meeting Q1 2026","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Initiated preclinical research in Type 2 diabetic animal models; in vivo proof-of-concept showed normalized glucose levels.","Submitted meeting request to FDA for Q1 2026 to discuss IND-enabling studies for GPX-002.","Transferred GPX-002 manufacturing to experienced CDMO; plans clinical-scale cGMP production.","Continuing construct optimization for second-generation GPX-002 using non-viral lipid nanoparticle delivery.","Toxicology studies to follow FDA interaction; data expected to enable IND filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8431010.683498647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105980,"accession_number":"0001437749-26-000437","cik":1595248,"company_name":"Genprex, Inc.","ticker":"GNPX","form_type":"8-K","filed_at":"2026-01-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Genprex reports positive preclinical GPX-002 data in T2D; first NHP achieved normal glucose tolerance at 7 months","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First T2D NHP received intraductal AAV infusion of GPX-002 (Pdx1+MafA) and showed normal glucose tolerance test at 7 months.","Second NHP via direct pancreas injection improved glucose tolerance at 3 months but did not reach normal levels.","T2D mice treated with GPX-002 showed reversal of hyperglycemia and normal glucose levels at 4 weeks post-surgery.","GPX-002 aims to rejuvenate exhausted beta cells; company says data supports potential to address 90-95% of diabetes patients (T2D).","Preclinical studies continuing; formal toxicology and IND submission planned."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":8431010.683498647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122271,"accession_number":"0001437749-25-038601","cik":1595248,"company_name":"Genprex, Inc.","ticker":"GNPX","form_type":"8-K","filed_at":"2025-12-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Genprex believes it now meets Nasdaq minimum equity requirement; Panel yet to rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Company raised proceeds from registered direct offerings (Oct 24 and 29, 2025), ATM with H.C. Wainwright, and equity line with Lincoln Park to boost equity.","Believes stockholders' equity now exceeds Nasdaq Listing Rule 5550(b)(1) minimum requirement.","Nasdaq Hearings Panel granted exception until Dec 31, 2025; has not yet determined compliance.","No assurance common stock will remain listed on Nasdaq Capital Market pending Panel decision."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8431010.683498647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122270,"accession_number":"0001437749-25-036380","cik":1595248,"company_name":"Genprex, Inc.","ticker":"GNPX","form_type":"8-K","filed_at":"2025-11-26T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Genprex (GNPX) regains Nasdaq bid price compliance, gets equity exception to Dec 31","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Panel confirmed Genprex regained compliance with Minimum Bid Price requirement ($1.00).","Panel granted exception through Dec 31, 2025 to meet Stockholders' Equity Requirement (Listing Rule 5550(b)(1)).","Company intends to raise additional capital to regain equity compliance; no assurance financing available on acceptable terms.","Panel may further extend to Feb 9, 2026 upon request, but no guarantee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":8431010.683498647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122269,"accession_number":"0001437749-25-036016","cik":1595248,"company_name":"Genprex, Inc.","ticker":"GNPX","form_type":"8-K","filed_at":"2025-11-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Genprex files to sell up to $75M in common stock via ATM with H.C. Wainwright","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed Nov 21, 2025 prospectus supplement for up to $75M of common stock under existing ATM agreement.","Prior sales: 796,065 shares for $14.8M gross proceeds since Dec 2023.","Proceeds for working capital and general corporate purposes; shares sold at market on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8431010.683498647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122268,"accession_number":"0001437749-25-035651","cik":1595248,"company_name":"Genprex, Inc.","ticker":"GNPX","form_type":"8-K","filed_at":"2025-11-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Genprex adds Gabrail Cancer Center as new site for Acclaim-1 and Acclaim-3 Reqorsa trials","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gabrail Cancer Center (Canton, OH) is new clinical trial site for Acclaim-1 (NSCLC) and Acclaim-3 (ES-SCLC) studying Reqorsa gene therapy.","Acclaim-1 Phase 2 expansion to enroll ~33 patients; interim analysis after 19 patients, enrollment of first 19 expected H1 2026.","Acclaim-3 Phase 2 expansion to enroll ~50 patients; interim analysis after 25th patient, enrollment of first 25 expected H1 2026.","Both trials have FDA Fast Track Designation; Acclaim-3 also has Orphan Drug Designation.","Phase 1 showed no dose-limiting toxicities and early efficacy: some patients had prolonged progression-free survival, one partial response."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":8431010.683498647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122267,"accession_number":"0001437749-25-035514","cik":1595248,"company_name":"Genprex, Inc.","ticker":"GNPX","form_type":"8-K","filed_at":"2025-11-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Genprex granted US patent for REQORSA plus PD-L1 antibody combo through 2037","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["USPTO patent covers REQORSA gene therapy combined with PD-L1 antibodies like Tecentriq, securing exclusivity to 2037.","Patents now granted in US and Korea; applications pending in Europe, Canada, Brazil, China, Israel.","Acclaim-3 Phase 1/2 trial for ES-SCLC combines REQORSA with Genentech's Tecentriq; Phase 2 expansion to enroll ~50 patients.","Interim analysis planned after 25th patient reaches 18 weeks; enrollment completion expected first half 2026.","Acclaim-3 has FDA Fast Track and Orphan Drug designations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8431010.683498647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122266,"accession_number":"0001437749-25-032870","cik":1595248,"company_name":"Genprex, Inc.","ticker":"GNPX","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Genprex announces European Patent Office intent to grant patent for Reqorsa with PD-1 antibodies","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["European Patent Office communicated intent to grant patent for Reqorsa gene therapy combined with PD-1 antibodies for cancer.","Existing patents already granted in US, Japan, Mexico, Russia, Australia, Chile, China, and Singapore.","Reqorsa initially developed for lung cancer with approved drugs; shown complementary in preclinical studies.","Company believes Reqorsa's unique attributes may improve current therapies for lung and other cancers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":8431010.683498647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122265,"accession_number":"0001437749-25-032081","cik":1595248,"company_name":"Genprex, Inc.","ticker":"GNPX","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Genprex raises ~$3.4M in registered direct offering plus up to $6.6M from warrant exercise","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering: 377,780 shares at $9.00/share; gross proceeds ~$3.4M before fees.","Concurrent private placement of warrants for 755,560 shares at $8.75 exercise price.","Warrants expire 24 months from effective date of resale registration statement.","Net proceeds expected ~$3.0M; use for working capital and general corporate purposes.","Closing expected on or about Oct 29, 2025; H.C. Wainwright as placement agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":8431010.683498647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122264,"accession_number":"0001437749-25-031856","cik":1595248,"company_name":"Genprex, Inc.","ticker":"GNPX","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Genprex reports positive preclinical data for Reqorsa in ALK+ NSCLC at AACR-NCI-EORTC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["REQORSA overexpressed TUSC2 tumor suppressor gene in ALK-EML4+ NSCLC cell lines and patient derived organoids.","Treatment induced apoptosis in ALK+ cells, including those resistant to alectinib; combination with alectinib further increased apoptosis.","In mouse xenograft model, REQORSA + alectinib improved survival vs control, suggesting potential for future clinical trial.","Data presented at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":8431010.683498647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122263,"accession_number":"0001437749-25-031678","cik":1595248,"company_name":"Genprex, Inc.","ticker":"GNPX","form_type":"8-K","filed_at":"2025-10-24T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Genprex announces $2.7M registered direct offering plus warrants for up to $5.4M; Nasdaq compliance risk remains","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 243,622 shares at $11.21/sh for ~$2.7M gross proceeds; net ~$2.3M after fees.","Concurrent private placement of warrants to purchase up to 487,244 shares at $11.00/sh, exercisable for 24 months.","Company still at risk of Nasdaq delisting; reverse stock split (1:50) implemented Oct 21, 2025; exception expires Oct 31, 2025.","Proceeds to be used for working capital and general corporate purposes.","H.C. Wainwright acting as placement agent; fees 7% cash plus warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":8431010.683498647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122262,"accession_number":"0001437749-25-031572","cik":1595248,"company_name":"Genprex, Inc.","ticker":"GNPX","form_type":"8-K","filed_at":"2025-10-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Genprex reports positive preclinical data for Reqorsa in ALK+ NSCLC at AACR-NCI-EORTC conference","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reqorsa plus alectinib shrank tumors by 79% vs 60% with alectinib alone in mouse xenograft model.","QO mediated TUSC2 overexpression induced apoptosis in ALK+ cell lines and patient-derived organoids.","Combination treatment showed reduced tumor regrowth 2 weeks after end of dosing vs single agents.","Data support potential clinical trial of Reqorsa for ALK-EML4 positive NSCLC patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":8431010.683498647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122261,"accession_number":"0001437749-25-031382","cik":1595248,"company_name":"Genprex, Inc.","ticker":"GNPX","form_type":"8-K","filed_at":"2025-10-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Genprex effects 1:50 reverse stock split; shares outstanding reduced to ~1M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split of common stock at 1:50 ratio effective October 21, 2025.","After split, approximately 1,004,326 shares of common stock outstanding (pre-rounding).","Previously disclosed; no change in par value or ticker symbol GNPX."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":8431010.683498647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122260,"accession_number":"0001437749-25-031210","cik":1595248,"company_name":"Genprex, Inc.","ticker":"GNPX","form_type":"8-K","filed_at":"2025-10-17T23:59:59+00:00","items":["3.01","3.03","5.03","7.01","8.01","9.01"],"status":"ready","headline":"Genprex granted Nasdaq exception through Oct 31, 2025; 1-for-50 reverse stock split effective Oct 21","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Nasdaq Panel exception to demonstrate compliance with $1.00 bid price and $2.5M stockholders' equity until Oct 31, 2025; Panel may extend to Feb 9, 2026.","1-for-50 reverse stock split filed Oct 16, effective Oct 21, 2025; CUSIP changes to 372446-302; symbol remains GNPX.","Acclaim-1 (REQORSA + Tagrisso) Phase 2a enrollment ongoing; interim analysis of first 19 patients expected H2 2026.","Acclaim-3 (REQORSA + Tecentriq) Phase 2 expansion enrolling; futility analysis after 25th patient expected H2 2026.","Diabetes gene therapy GPX-002 in preclinical studies; plans to request FDA meeting for IND-enabling studies by end of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":8431010.683498647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138970,"accession_number":"0001437749-25-027451","cik":1595248,"company_name":"Genprex, Inc.","ticker":"GNPX","form_type":"8-K","filed_at":"2025-08-20T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Genprex faces Nasdaq delisting for both equity and bid price non-compliance; hearing requested","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' equity of $1.39M as of June 30, 2025, below Nasdaq's $2.5M minimum requirement.","Also non-compliant with $1.00 bid price rule; previous delisting determination from Aug 12, 2025.","Company requested a hearing on Aug 19, 2025, which stays delisting pending Panel decision.","No assurance that Panel will grant continued listing or extension."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":8431010.683498647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138969,"accession_number":"0001437749-25-027191","cik":1595248,"company_name":"Genprex, Inc.","ticker":"GNPX","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Genprex gets US and EU patent allowances for REQORSA combo with PD-L1/PD-1 antibodies; trial underway","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["USPTO issued notice of allowance for patent covering REQORSA + PD-L1 antibodies (e.g., Tecentriq); EPO issued allowance for REQORSA + PD-1 antibodies; both expire 2037.","Korea granted patent for REQORSA + PD-L1 antibodies; Genprex pursuing additional patents in Europe, Canada, Brazil, China, Israel for Acclaim-3 trial.","Patents for REQORSA + PD-1 antibodies already granted in US, Japan, Mexico, Russia, Australia, Chile, China, Korea, and Singapore.","Acclaim-3 Phase 1/2 trial testing REQORSA + Tecentriq maintenance in ES-SCLC has FDA Fast Track and Orphan Drug Designation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":8431010.683498647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138968,"accession_number":"0001437749-25-027138","cik":1595248,"company_name":"Genprex, Inc.","ticker":"GNPX","form_type":"8-K","filed_at":"2025-08-15T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Genprex stockholders approve reverse split (1:10-1:50), 6.5M new shares for equity plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approved Amended & Restated 2018 Equity Plan, adding 6,500,000 shares and extending term to June 30, 2035.","Authorized reverse stock split at ratio between 1:10 and 1:50, to be implemented at Board's discretion before Dec 31, 2026.","Approved issuance of >20% of common stock to Lincoln Park Capital Fund under purchase agreement.","Stockholders ratified WithumSmith+Brown as independent auditor for FY2025 with 14.2M votes for vs 1.5M against.","Director William R. Wilson Jr. reelected with 5.6M votes for; broker non-votes of 9.6M on multiple proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.72,"calibrated_materiality_score":0.72,"market_cap_usd":8431010.683498647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138967,"accession_number":"0001437749-25-024487","cik":1595248,"company_name":"Genprex, Inc.","ticker":"GNPX","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Genprex issues 2025 corporate update; two lung cancer trials ongoing","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Patient treatment continues in two lung cancer clinical trials.","Company highlights clinical milestones across oncology and diabetes programs.","CEO Ryan Confer cites progress and upcoming milestones for H2 2025 and beyond.","No specific financial results or enrollment numbers disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":8431010.683498647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156457,"accession_number":"0001437749-25-021093","cik":1595248,"company_name":"Genprex, Inc.","ticker":"GNPX","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Genprex reports positive preclinical data for diabetes gene therapy GPX-002 at ADA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Alpha cells in Type 1 diabetes mouse models transdifferentiated to insulin-secreting beta-like cells after GPX-002 infusion.","In diabetic non-human primates, GPX-002 improved glucose tolerance and reduced insulin requirements at one month post-infusion.","Three-month immunosuppression with rituximab, rapamycin, and steroids largely prevented anti-viral immunity in NHPs.","Continued studies will evaluate GPX-002 efficacy after six months of immunosuppression in NHP models."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":8431010.683498647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156456,"accession_number":"0001437749-25-020977","cik":1595248,"company_name":"Genprex, Inc.","ticker":"GNPX","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Genprex reports positive preclinical data for GPX-002 using lipid nanoparticle delivery at ADA 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nine LNPs tested; two were highly efficient in transfecting α- and β-cells in isolated mouse islets.","LNP using ALX-184 with mRNA payload injected into mouse common bile duct efficiently transfected pancreatic cells.","Non-viral LNP approach could enable repeat dosing and may eliminate need for immunosuppression.","Research presented at ADA 85th Scientific Sessions in Chicago; builds on ongoing AAV-based studies.","Company views results as proof-of-concept for a next-generation diabetes gene therapy delivery system."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8431010.683498647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156455,"accession_number":"0001437749-25-020102","cik":1595248,"company_name":"Genprex, Inc.","ticker":"GNPX","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Genprex secures $12.5M equity line with Lincoln Park; provides clinical trial updates","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered purchase agreement for up to $12.5M in common stock; issued 1,186,859 commitment shares to Lincoln Park.","Acclaim-1 Phase 2a expansion targets ~33 patients; interim analysis of first 19 expected Q1 2026, top-line in H1 2026.","Acclaim-3 Phase 2 expansion plans ~50 patients; futility analysis after 25 patients expected Q1 2026.","Both Acclaim-1 and Acclaim-3 have FDA Fast Track designation; Acclaim-3 also has Orphan Drug Designation.","Proceeds from Lincoln Park sales to be used for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8431010.683498647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156454,"accession_number":"0001437749-25-019767","cik":1595248,"company_name":"Genprex, Inc.","ticker":"GNPX","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Genprex regains Nasdaq stockholders' equity compliance; bid price issue unresolved","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq confirmation on June 6, 2025 that it regained compliance with stockholders' equity requirement of $2.5M.","Previously reported non-compliance with minimum bid price of $1.00 per share; compliance period ends August 6, 2025.","Company may consider reverse stock split or other options to regain bid price compliance; delisting risk remains."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8431010.683498647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156453,"accession_number":"0001437749-25-014909","cik":1595248,"company_name":"Genprex, Inc.","ticker":"GNPX","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Genprex enters new sponsored research agreement with University of Pittsburgh for GPX-002 diabetes gene therapy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New SRA with Pitt for preclinical studies of GPX-002 in T1D and T2D animal models.","Preclinical T1D data showed statistically significant decreases in insulin requirements and increases in c-peptide levels.","GPX-002 uses adeno-associated virus vector with Pdx1 and MafA genes delivered via pancreatic duct.","In T1D, GPX-002 aims to transform alpha cells into functional beta-like cells to evade immune system.","In T2D, GPX-002 is believed to rejuvenate exhausted beta cells."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8431010.683498647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156452,"accession_number":"0001437749-25-014618","cik":1595248,"company_name":"Genprex, Inc.","ticker":"GNPX","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Genprex licenses exclusive patent rights to Reqorsa for glioblastoma from UTHealth Houston","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive patent license with UTHealth Houston grants Genprex commercial rights to Reqorsa for GBM.","Previous positive preclinical data (Oct 2024) showed Reqorsa reduced GBM cell viability and suppressed migration.","TUSC2 tumor suppressor identified as novel target for glioblastoma by UTHealth Houston researchers.","Company believes results support further in vivo evaluation in malignant glioma mouse models."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":8431010.683498647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156451,"accession_number":"0001437749-25-013235","cik":1595248,"company_name":"Genprex, Inc.","ticker":"GNPX","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Genprex licenses NYU patent for Reqorsa gene therapy in mesothelioma; TUSC2 down in 84%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive patent license with NYU Langone Health for Reqorsa (quaratusugene ozeplasmid) to treat mesothelioma.","TUSC2 tumor suppressor gene is downregulated in 84% of mesotheliomas; Reqorsa delivers TUSC2.","Preclinical data showed decreased cell proliferation/invasion and increased apoptosis in all four MPM cell lines.","Genprex formed a Mesothelioma Clinical Advisory Board of four leading researchers to guide the program.","About 3,000 new US cases/yr; life expectancy 18 months, 3-year survival rate 23% with treatment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8431010.683498647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174892,"accession_number":"0001437749-25-004126","cik":1595248,"company_name":"Genprex, Inc.","ticker":"GNPX","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["1.01","1.02","7.01","8.01","9.01"],"status":"ready","headline":"Genprex signs amended exclusive license with Univ of Pittsburgh for diabetes gene therapy, forms subsidiary","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered amended and restated exclusive license with Univ of Pittsburgh for T1D and T2D gene therapy using Pdx1 and MafA genes.","License includes milestone payments up to approximately $4,825,000 and low single-digit royalties on sales.","Terminated prior license agreements, including the November 2022 macrophage technology license.","Formed wholly-owned subsidiary Convergen Biotech, Inc. to focus on diabetes program development.","Plans to request FDA guidance for IND-enabling diabetes studies by the second half of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8431010.683498647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174891,"accession_number":"0001437749-25-003490","cik":1595248,"company_name":"Genprex, Inc.","ticker":"GNPX","form_type":"8-K","filed_at":"2025-02-12T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Genprex receives Nasdaq deficiency notices for bid price and equity requirements","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Genprex on Feb 7, 2025 that its stock closed below $1.00 for 30 consecutive business days, non-compliant with Rule 5550(a)(2).","Company has 180 days, until Aug 6, 2025, to regain compliance by having bid price at $1.00+ for 10 consecutive days.","On Feb 11, 2025, Staff granted extension for prior stockholders' equity deficiency; must report $2.5M equity by Q1 2025 10-Q filing due May 15, 2025.","Company faces risk of delisting if it fails to meet either requirement; can appeal but no assurance of success."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":8431010.683498647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174890,"accession_number":"0001437749-25-001630","cik":1595248,"company_name":"Genprex, Inc.","ticker":"GNPX","form_type":"8-K","filed_at":"2025-01-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Genprex doses first patient in Phase 2 expansion of Acclaim-3 trial for Reqorsa + Tecentriq in ES-SCLC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 expansion will enroll ~50 patients at 10-15 U.S. sites; primary endpoint is 18-week progression-free survival rate.","Recommended Phase 2 dose of Reqorsa set at 0.12 mg/kg (highest Phase 1 dose), no dose-limiting toxicities observed.","Interim analysis planned after first 25 patients reach 18 weeks of follow-up; enrollment of initial 25 expected in H2 2025.","Acclaim-3 holds FDA Fast Track and Orphan Drug Designations for this extensive-stage small cell lung cancer indication."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":8431010.683498647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174889,"accession_number":"0001437749-25-000932","cik":1595248,"company_name":"Genprex, Inc.","ticker":"GNPX","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Genprex provides clinical trial updates for Acclaim-1, Acclaim-3, and diabetes gene therapy program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Acclaim-1 Phase 2a expansion enrolling; interim analysis after 19 patients expected H2 2025.","Acclaim-3 Phase 2 expansion opened; enrollment of first 25 patients for interim analysis expected H2 2025.","Diabetes gene therapy program licensed from Univ. of Pittsburgh; seeking FDA guidance for IND-enabling studies in H2 2025.","Acclaim-1 has FDA Fast Track; Acclaim-3 has Fast Track and Orphan Drug designations.","Initiated research on non-viral lipid nanoparticle delivery system for diabetes program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":8431010.683498647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191843,"accession_number":"0001437749-24-037525","cik":1595248,"company_name":"Genprex, Inc.","ticker":"GNPX","form_type":"8-K","filed_at":"2024-12-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Genprex completes Phase 1 dose escalation of Reqorsa + Tecentriq in ES-SCLC; Phase 2 opens","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["No dose-limiting toxicities observed; RP2D set at 0.12 mg/kg (highest dose tested).","Safety Review Committee approved opening Phase 2 expansion; enrollment has started.","Phase 2 will enroll ~50 patients at 10-15 U.S. sites; primary endpoint is 18-week PFS rate.","Futility analysis after 25th patient reaches 18 weeks of follow-up.","Acclaim-3 has FDA Fast Track and Orphan Drug designations for ES-SCLC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8431010.683498647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191842,"accession_number":"0001437749-24-035812","cik":1595248,"company_name":"Genprex, Inc.","ticker":"GNPX","form_type":"8-K","filed_at":"2024-11-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Genprex enters exclusive license with Univ of Michigan for Reqorsa in ALK+ lung cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["License grants Genprex worldwide exclusive rights to University of Michigan patents for Reqorsa gene therapy combined with ALK-inhibitors for ALK-EML4 positive NSCLC.","Preclinical data at AACR April 2024 showed Reqorsa induced apoptosis in alectinib-resistant EML4-ALK positive NSCLC cell lines.","Researchers believe results support further clinical study of Reqorsa as an anti-ALK NSCLC treatment strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":8431010.683498647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191841,"accession_number":"0001437749-24-035757","cik":1595248,"company_name":"Genprex, Inc.","ticker":"GNPX","form_type":"8-K","filed_at":"2024-11-19T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Genprex receives Nasdaq delisting notice for failing minimum stockholders' equity requirement","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' equity of $1,664,971 as of Sept 30, 2024, below the Nasdaq minimum of $2.5 million.","Company has 45 days, until Jan 3, 2025, to submit a plan to regain compliance.","If plan accepted, Nasdaq may grant up to 180 days extension; no assurance of success.","Failure could lead to delisting from Nasdaq Capital Market; company evaluating options."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":8431010.683498647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191840,"accession_number":"0001437749-24-033217","cik":1595248,"company_name":"Genprex, Inc.","ticker":"GNPX","form_type":"8-K","filed_at":"2024-11-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Genprex regains Nasdaq minimum bid price compliance; delisting risk resolved","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received Nasdaq letter on Nov 4, 2024 confirming compliance with Listing Rule 5550(a)(2).","Previously notified of non-compliance on Sept 26, 2024 due to bid price below $1.00 for 30 consecutive days.","Matter is now closed; company continues trading on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8431010.683498647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191839,"accession_number":"0001437749-24-031966","cik":1595248,"company_name":"Genprex, Inc.","ticker":"GNPX","form_type":"8-K","filed_at":"2024-10-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Genprex partners with U Michigan to study REQORSA plus ALK-inhibitors in ALK+ lung cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered Sponsored Research Agreement with Univ. of Michigan Rogel Cancer Center for TUSC2/REQORSA combo with ALK-inhibitors.","Collaboration with ALK Positive nonprofit; both share cost of the SRA.","Preclinical data (AACR Apr 2024): REQORSA induced apoptosis in alectinib-resistant EML4-ALK+ NSCLC lines.","TUSC2 overexpression via REQORSA decreased cell growth and proliferation through apoptotic pathway activation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":8431010.683498647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191838,"accession_number":"0001437749-24-031202","cik":1595248,"company_name":"Genprex, Inc.","ticker":"GNPX","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Genprex completes 0.09 mg/kg dose in Phase 1 Acclaim-3 trial; SRC approves escalation to highest dose","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Completed 0.09 mg/kg dose group of Reqorsa + Tecentriq in ES-SCLC Phase 1; no dose-limiting toxicities reported.","Safety Review Committee approved escalation to 0.12 mg/kg, the highest planned dose group.","Phase 2 expansion will enroll 50 patients at 10-15 U.S. sites; primary endpoint is 18-week PFS rate.","Acclaim-3 has FDA Fast Track and Orphan Drug Designations for this patient population.","Company expects to start Phase 2 expansion in H2 2024, pending enrollment in the 0.12 mg/kg cohort."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":8431010.683498647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208323,"accession_number":"0001437749-24-030088","cik":1595248,"company_name":"Genprex, Inc.","ticker":"GNPX","form_type":"8-K","filed_at":"2024-09-26T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Genprex receives Nasdaq deficiency notice for bid price below $1.00; 180-day cure period","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq letter dated Sept 26, 2024; stock fails minimum $1.00 bid price for 30 consecutive business days.","Cure period ends March 25, 2025; must have $1.00 closing bid for 10 consecutive days to regain compliance.","Company may qualify for additional 180-day period if it meets other listing standards and notifies Nasdaq.","Potential actions include reverse stock split; delisting risk if unable to cure.","Common stock continues trading on Nasdaq Capital Market while Company monitors bid price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":8431010.683498647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208322,"accession_number":"0001437749-24-028339","cik":1595248,"company_name":"Genprex, Inc.","ticker":"GNPX","form_type":"8-K","filed_at":"2024-09-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Genprex to spin out diabetes gene therapy program into new subsidiary GPX-002","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Intends to transfer diabetes clinical development and gene therapy assets to wholly-owned NewCo.","NewCo will focus on GPX-002 for Type 1 and Type 2 diabetes; Genprex retains oncology programs.","Spin-out expected by end of 2024, subject to financing, conditions, and board approval.","Reorganization follows recent refocus on oncology lead Reqorsa Gene Therapy for expedited regulatory submission.","Company continues to evaluate strategic alternatives to enhance stockholder value."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":8431010.683498647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208321,"accession_number":"0001437749-24-026166","cik":1595248,"company_name":"Genprex, Inc.","ticker":"GNPX","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Genprex granted Singapore patent for Reqorsa with anti-PD-1 antibodies through 2037","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Singapore Patent Office grants patent covering Reqorsa (quaratusugene ozeplasmid) in combo with anti-PD-1 antibodies until 2037.","Patent expands on previously granted patents in U.S., Japan, Mexico, Russia, Australia, Chile, China, and Korea.","Korean patent also claims Reqorsa with PD-L1 antibodies; Genprex plans similar filings in U.S., Brazil, Canada, China, Europe, Israel.","Patent supports Acclaim-3 Phase 1/2 trial for ES-SCLC maintenance therapy combining Reqorsa with Tecentriq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8431010.683498647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225948,"accession_number":"0001437749-24-021339","cik":1595248,"company_name":"Genprex, Inc.","ticker":"GNPX","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Genprex begins treating patients in two new lung cancer trials, continues third","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Opened enrollment and began treating patients in two new lung cancer clinical trials in 2024.","Continues treating patients in a third lung cancer clinical trial.","Partnered with community-based oncology practices to broaden clinical study reach.","Expanded preclinical programs into new indications; presented positive data at major cancer conference.","Strengthened global IP estate for lead drug candidate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":8431010.683498647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225947,"accession_number":"0001437749-24-021031","cik":1595248,"company_name":"Genprex, Inc.","ticker":"GNPX","form_type":"8-K","filed_at":"2024-06-24T23:59:59+00:00","items":["5.02","5.07","8.01","9.01"],"status":"ready","headline":"Genprex CEO Confer Gets Salary Hike, Title Upgrade; Former EVP Vaczy Receives $350K Severance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ryan Confer confirmed as President, CEO and CFO; base salary increased to $480,000 per year; severance reference period extended from 12 to 18 months.","Separating EVP Catherine Vaczy receives $300,000 plus $50,000 severance, acceleration of 6,125 RSUs and 4,374 options.","At June 18 annual meeting, director Brent Longnecker elected; ratification of WithumSmith+Brown as auditor; advisory say-on-pay approved and frequency set to every year.","Board adopted amended Outside Director Compensation Policy adding $15,000 annual cash retainer for non-executive Chairman."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8431010.683498647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225946,"accession_number":"0001437749-24-015471","cik":1595248,"company_name":"Genprex, Inc.","ticker":"GNPX","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Genprex CEO Rodney Varner dies; CFO Ryan Confer appointed CEO and Board member","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO/President/Chairman Rodney Varner passed away unexpectedly on May 7, 2024 due to illness complications.","Ryan Confer, CFO since 2016, appointed President and CEO effective May 8, 2024; also named to Board as Class III director.","Confer will continue as CFO until a permanent CFO is identified; Board has started a search.","Compensation Committee plans to review Confer's compensation in light of new responsibilities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":8431010.683498647,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2024-05-09T23:59:59+00:00|225946"}